

### POSTER PRESENTATION



# B7-h3-specific engager T cells for the immunotherapy of pediatric solid tumors

Christopher DeRenzo<sup>1\*</sup>, David Torres<sup>1</sup>, Victoria Tobin<sup>1</sup>, Phuong Nguyen<sup>1</sup>, Xiao-Tong Song<sup>1</sup>, Stephen Gottschalk<sup>2</sup>

*From* 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

National Harbor, MD, USA. 4-8 November 2015

#### Background

B7-H3 positive tumors, including osteosarcoma, neuroblastoma, and high grade glioma, cause significant morbidity and mortality despite aggressive multimodality treatments. Current B7-H3-targeted immune-therapies take advantage of the monoclonal antibody 8H9, which is actively being evaluated in Phase I clinical trials. Engager T cells, which secrete bispecific engager molecules consisting of single chain variable fragments specific for CD3 and a tumor antigen, are a new class of antigen-specific T cells, with the unique ability to redirect bystander T cells to tumors, amplifying anti-tumor effects. The goal of this project was to develop B7-H3-specific Engager T cells, and pre-clinically evaluate their effector function *in vitro* and *in vivo*.


#### Methods


B7-H3-Engager T cells were generated by transducing T cells with a retroviral vector encoding a B7-H3-specific T cell engager and mOrange separated by an internal ribosomal entry site. B7-H3-Engager T cell effector function was then evaluated *in vitro* and in a metastatic osteosarcoma xenograft model.

#### Results

Post transduction 70-84% of T cells were positive for transgene expression. In coculture assay B7-H3-Engager T cells recognized B7-H3-positive osteosarcoma (LM7), neuroblastoma (CHLA255), and glioma (U373) cell lines, as judged by IFN- $\gamma$  secretion, in contrast to B7-H3-negative tumor cells (HTB-119) (Figure 1). None of the targets were recognized by T cells secreting engager molecules specific for an irrelevant antigen (CD19-Engager T cells). Antigen-dependent recognition was

<sup>1</sup>Baylor College of Medicine, Houston, TX, USA Full list of author information is available at the end of the article






confirmed in standard cytotoxicity assays (Figure 2). To assess anti-tumor activity of B7-H3-Engager T cells *in vivo* we used a metastatic osteosarcoma xenograft model that allows for serial bioluminescence imaging of LM7 cells that are genetically modified to express the fire fly



© 2015 DeRenzo et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated.



luciferase gene (LM7-ffLuc). NSG mice were intravenously injected with LM7-ffLuc cells, followed by intravenous doses of B7-H3-Engager or control (CD19-Engager) T cells on days 28 and 35 post LM7-ffLuc injection. In contrast to control T cells, B7-H3-Engager T cells had potent anti-osteosarcoma activity (Figure 3) resulting in a survival advantage of treated mice.

#### Conclusions

We successfully generated B7-H3-Engager T cells and demonstrate that these cells recognize and kill B7-H3-positive tumor cells in an antigen-dependent manner, and have potent anti-osteosarcoma activity *in vivo*. Thus, B7-H3-Engager T cells may present a promising alternative to current T cell immunotherapy approaches for pediatric solid tumors.

#### Authors' details

<sup>1</sup>Baylor College of Medicine, Houston, TX, USA. <sup>2</sup>Baylor College of Medicine, Center for Cell and Gene Therapy, Department of Pediatrics, Houston, TX, USA.

Published: 4 November 2015

#### doi:10.1186/2051-1426-3-S2-P11

**Cite this article as:** DeRenzo *et al.*: **B7-h3-specific engager T cells for the immunotherapy of pediatric solid tumors.** *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P11.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) Bio Med Central

Submit your manuscript at www.biomedcentral.com/submit